« Return to News | CROs/Service Providers

Quintiles launches Kun Tuo

Tuesday, December 13, 2011 09:51 AM

Quintiles has launched Kun Tuo, a local contract research organization built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.

Kun Tuo will focus on developing customized solutions to help local and global biopharma companies achieve successful registration of new medicines in China. Kun Tuo will provide a full range of services, including comprehensive clinical trial management, regulatory submission preparation, biostatistics and data management. Kun Tuo will tap Quintiles’ global resources and expertise to develop customized offerings in key therapeutic areas, along with vaccines, late phase studies, medical devices and diagnostics.

“Kun Tuo will leverage Quintiles’ quality and training systems to offer customized, high-quality solutions best suited for local Chinese biopharma, as well as global biopharma local affiliates,” said Ling Zhen, general manager, Quintiles China. “We have an aggressive growth plan for China and anticipate doubling Quintiles total staff during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world’s most dynamic marketplaces.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.